The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates

Tim Taber, Muhammad Mujtaba, William Goggins, Nancy Higgins, Asif Sharfuddin, Muhammad Sohail Yaqub, Dennis Mishler, Benita Book, Jeanne Chen, Andrew Lobashevsky

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Kidney transplantation faces many challenges not the least of which is the presence of pre-formed HLA antibodies. At our institution, we have used a combination of methods to immunomodulate sensitized patients. Most recently, this has been attempted with a combination of immunoglobulin (IVIG) and rituximab (Rituxan; Genetech, CA, USA). A total of 31 patients were followed for up to one yr following treatment with IVIG (2 gm/kg on day 1 and day 30) and rituximab (1 g - day 15). Antibody levels were followed serially at designated time points via solid-phase single-antigen beads (SAB) method (One Lambda, Inc., Canoga Park, CA, USA). Concentration of antibodies was based on median fluorescence intensity (MFI). The majority of patients had both class I and class II antibodies (79%). Our results showed that this protocol appeared to be patient and antibody specific. The most pronounced MFI reduction in antibodies occurred within the 30- to 100-d period post-treatment. Calculated panel-reactive antibodies decreased but rebound tended to occur by 104 d after antibody MFI nadir. Because of this rebound, it can be inferred that the patients did not show a durable increase in their potential for transplantation. The search for a more effective method to immunomodulate patients continues.

Original languageEnglish (US)
JournalClinical Transplantation
Volume27
Issue number4
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Immunomodulation
Immunoglobulins
Transplants
Kidney
Antibodies
Fluorescence
Intravenous Immunoglobulins
Immunoglobulin Isotypes
Rituximab
Kidney Transplantation
Transplantation
Antigens
Therapeutics

Keywords

  • Antibodies
  • Immunomodulation
  • Kidney
  • Sensitized
  • Transplant

ASJC Scopus subject areas

  • Transplantation

Cite this

The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates. / Taber, Tim; Mujtaba, Muhammad; Goggins, William; Higgins, Nancy; Sharfuddin, Asif; Yaqub, Muhammad Sohail; Mishler, Dennis; Book, Benita; Chen, Jeanne; Lobashevsky, Andrew.

In: Clinical Transplantation, Vol. 27, No. 4, 07.2013.

Research output: Contribution to journalArticle

Taber, Tim ; Mujtaba, Muhammad ; Goggins, William ; Higgins, Nancy ; Sharfuddin, Asif ; Yaqub, Muhammad Sohail ; Mishler, Dennis ; Book, Benita ; Chen, Jeanne ; Lobashevsky, Andrew. / The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates. In: Clinical Transplantation. 2013 ; Vol. 27, No. 4.
@article{d0eb839343344e74bded81b0a7c93408,
title = "The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates",
abstract = "Kidney transplantation faces many challenges not the least of which is the presence of pre-formed HLA antibodies. At our institution, we have used a combination of methods to immunomodulate sensitized patients. Most recently, this has been attempted with a combination of immunoglobulin (IVIG) and rituximab (Rituxan; Genetech, CA, USA). A total of 31 patients were followed for up to one yr following treatment with IVIG (2 gm/kg on day 1 and day 30) and rituximab (1 g - day 15). Antibody levels were followed serially at designated time points via solid-phase single-antigen beads (SAB) method (One Lambda, Inc., Canoga Park, CA, USA). Concentration of antibodies was based on median fluorescence intensity (MFI). The majority of patients had both class I and class II antibodies (79{\%}). Our results showed that this protocol appeared to be patient and antibody specific. The most pronounced MFI reduction in antibodies occurred within the 30- to 100-d period post-treatment. Calculated panel-reactive antibodies decreased but rebound tended to occur by 104 d after antibody MFI nadir. Because of this rebound, it can be inferred that the patients did not show a durable increase in their potential for transplantation. The search for a more effective method to immunomodulate patients continues.",
keywords = "Antibodies, Immunomodulation, Kidney, Sensitized, Transplant",
author = "Tim Taber and Muhammad Mujtaba and William Goggins and Nancy Higgins and Asif Sharfuddin and Yaqub, {Muhammad Sohail} and Dennis Mishler and Benita Book and Jeanne Chen and Andrew Lobashevsky",
year = "2013",
month = "7",
doi = "10.1111/ctr.12142",
language = "English (US)",
volume = "27",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates

AU - Taber, Tim

AU - Mujtaba, Muhammad

AU - Goggins, William

AU - Higgins, Nancy

AU - Sharfuddin, Asif

AU - Yaqub, Muhammad Sohail

AU - Mishler, Dennis

AU - Book, Benita

AU - Chen, Jeanne

AU - Lobashevsky, Andrew

PY - 2013/7

Y1 - 2013/7

N2 - Kidney transplantation faces many challenges not the least of which is the presence of pre-formed HLA antibodies. At our institution, we have used a combination of methods to immunomodulate sensitized patients. Most recently, this has been attempted with a combination of immunoglobulin (IVIG) and rituximab (Rituxan; Genetech, CA, USA). A total of 31 patients were followed for up to one yr following treatment with IVIG (2 gm/kg on day 1 and day 30) and rituximab (1 g - day 15). Antibody levels were followed serially at designated time points via solid-phase single-antigen beads (SAB) method (One Lambda, Inc., Canoga Park, CA, USA). Concentration of antibodies was based on median fluorescence intensity (MFI). The majority of patients had both class I and class II antibodies (79%). Our results showed that this protocol appeared to be patient and antibody specific. The most pronounced MFI reduction in antibodies occurred within the 30- to 100-d period post-treatment. Calculated panel-reactive antibodies decreased but rebound tended to occur by 104 d after antibody MFI nadir. Because of this rebound, it can be inferred that the patients did not show a durable increase in their potential for transplantation. The search for a more effective method to immunomodulate patients continues.

AB - Kidney transplantation faces many challenges not the least of which is the presence of pre-formed HLA antibodies. At our institution, we have used a combination of methods to immunomodulate sensitized patients. Most recently, this has been attempted with a combination of immunoglobulin (IVIG) and rituximab (Rituxan; Genetech, CA, USA). A total of 31 patients were followed for up to one yr following treatment with IVIG (2 gm/kg on day 1 and day 30) and rituximab (1 g - day 15). Antibody levels were followed serially at designated time points via solid-phase single-antigen beads (SAB) method (One Lambda, Inc., Canoga Park, CA, USA). Concentration of antibodies was based on median fluorescence intensity (MFI). The majority of patients had both class I and class II antibodies (79%). Our results showed that this protocol appeared to be patient and antibody specific. The most pronounced MFI reduction in antibodies occurred within the 30- to 100-d period post-treatment. Calculated panel-reactive antibodies decreased but rebound tended to occur by 104 d after antibody MFI nadir. Because of this rebound, it can be inferred that the patients did not show a durable increase in their potential for transplantation. The search for a more effective method to immunomodulate patients continues.

KW - Antibodies

KW - Immunomodulation

KW - Kidney

KW - Sensitized

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84881557213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881557213&partnerID=8YFLogxK

U2 - 10.1111/ctr.12142

DO - 10.1111/ctr.12142

M3 - Article

VL - 27

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4

ER -